Remimazolam for sedation and anesthesia in children: A scoping review
Open Access
- 9 May 2024
- journal article
- research article
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 68 (7) , 862-870
Abstract
Background: Remimazolam, a novel intravenous benzodiazepine recently approved by both the European Medicines Agency and the Food and Drug Agency, shows considerable promise in clinical practice. Its pharmacodynamic profile closely resembles that of midazolam, while its pharmacokinetic properties are similar to those of remifentanil. While research in adult populations continues to accumulate, the pace of pediatric studies is not as significant.This scoping review aims to systematically examine published studies, clinical trials, observational research, case reports, and relevant literature to provide a comprehensive understanding of remimazolam in pediatric sedation and anesthesia. By synthesizing the gathered evidence, we aim to identify gaps in the literature, guide future research endeavors, and inform clinical practices.Methods: The review follows the guidelines outlined by the Preferred Reporting Items for Systematic Review and Meta‐Analysis for Scoping Review. A thorough search strategy was implemented across prominent peer‐reviewed databases, with focused efforts to identify relevant grey literature. All primary studies involving the use of remimazolam in pediatric populations were included in this review.Results: Eighteen studies were included in this analysis, comprising 2 randomized controlled trials, 4 prospective cohort trials, 12 case reports, and 692 children in total.Conclusion: This scoping review highlights the increasing interest in using remimazolam as a sedative or anesthetic for children. Although initial evidence indicates its effectiveness and safety, more research is necessary to fill knowledge gaps, establish standard protocols, and optimize its use in pediatric anesthesia and sedation. Addressing these challenges will enable clinicians to improve the quality of care and outcomes for pediatric patients undergoing sedation and anesthesia.Keywords
This publication has 28 references indexed in Scilit:
- Remimazolam for sedation and anesthesia in children: Protocol for a scoping reviewActa Anaesthesiologica Scandinavica, 2024
- Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised childrenBritish Journal of Anaesthesia, 2023
- Remimazolam and serious adverse eventsEuropean Journal of Anaesthesiology, 2023
- Remimazolam – current status, opportunities and challengesAnesthesiology and Perioperative Science, 2023
- Remimazolam: Is the quest for the holy grail of sedation during diagnostic or endoscopic interventions over?European Journal of Anaesthesiology, 2022
- Anaphylaxis following remimazolam administration during induction of anaesthesiaBritish Journal of Anaesthesia, 2022
- Two cases of circulatory collapse due to suspected remimazolam anaphylaxisJA Clinical Reports, 2022
- Anesthetic management with remimazolam for a pediatric patient with Duchenne muscular dystrophyMedicine, 2021
- Online tools supporting the conduct and reporting of systematic reviews and systematic maps: a case study on CADIMA and review of existing toolsEnvironmental Evidence, 2018
- New Hypnotic Drug Development and Pharmacologic Considerations for Clinical AnesthesiaAnesthesiology Clinics, 2017